Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subject Index Vol. 33, No. 6, 2015

Subject Index Vol. 33, No. 6, 2015 Adverse events  728 Intermediate stage  751 Aging  745 International working group  721 Apoptosis  771 Arterioportal angiography  721 Japanese population  715 Background liver  745 Liver cancer  735 BCLC staging  751 Locoregional therapy  765 Cancer stem cell  771 Maximum intensity projection  759 Chemoresistance  771 MicroRNA  771 Chronic hepatitis C  708 Cirrhosis  735 Non-alcoholic fatty liver disease  715 CK-18M65  715 – steatohepatitis  715 Clinical research  780 NS3/4 protease inhibitors  708 Cone-beam CT angiography  759 Contrast media  735 Practice guideline  765 Primary liver cancer  765 Diabetes mellitus  745 Prospective randomized clinical trial  Diagnosis  780 780 Differential diagnosis  735 DNA methylation  745 RECICL  728 Response evaluation criteria in cancer of Early HCC  721 the liver  765 Epithelial-mesenchymal transition  771 Response-guided therapy  708 Gd-EOB-DTPA MRI  721 Serum biomarker  715 General rules  765 Signaling pathway  771 Simeprevir  708 Hepatobiliary phase  721 Sorafenib  728, 771 Hepatocellular carcinoma  728, 735, 745, 751, 759, 765, 771, 780 Transarterial chemoembolization  751 Hypovascular well-differentiated HCC  Transcatheter arterial 721 chemoembolization  759 Treatment  780 Imaging detectability  721 Immunity  771 Volume rendering  759 Interferon  708 © 2015 S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/ddi http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Digestive Diseases Karger

Subject Index Vol. 33, No. 6, 2015

Digestive Diseases , Volume 33 (6): 1 – Jan 1, 2015

Loading next page...
 
/lp/karger/subject-index-vol-33-no-6-2015-lDjagrwF9r

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2015 S. Karger AG, Basel
ISSN
0257-2753
eISSN
1421-9875
DOI
10.1159/000439471
Publisher site
See Article on Publisher Site

Abstract

Adverse events  728 Intermediate stage  751 Aging  745 International working group  721 Apoptosis  771 Arterioportal angiography  721 Japanese population  715 Background liver  745 Liver cancer  735 BCLC staging  751 Locoregional therapy  765 Cancer stem cell  771 Maximum intensity projection  759 Chemoresistance  771 MicroRNA  771 Chronic hepatitis C  708 Cirrhosis  735 Non-alcoholic fatty liver disease  715 CK-18M65  715 – steatohepatitis  715 Clinical research  780 NS3/4 protease inhibitors  708 Cone-beam CT angiography  759 Contrast media  735 Practice guideline  765 Primary liver cancer  765 Diabetes mellitus  745 Prospective randomized clinical trial  Diagnosis  780 780 Differential diagnosis  735 DNA methylation  745 RECICL  728 Response evaluation criteria in cancer of Early HCC  721 the liver  765 Epithelial-mesenchymal transition  771 Response-guided therapy  708 Gd-EOB-DTPA MRI  721 Serum biomarker  715 General rules  765 Signaling pathway  771 Simeprevir  708 Hepatobiliary phase  721 Sorafenib  728, 771 Hepatocellular carcinoma  728, 735, 745, 751, 759, 765, 771, 780 Transarterial chemoembolization  751 Hypovascular well-differentiated HCC  Transcatheter arterial 721 chemoembolization  759 Treatment  780 Imaging detectability  721 Immunity  771 Volume rendering  759 Interferon  708 © 2015 S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/ddi

Journal

Digestive DiseasesKarger

Published: Jan 1, 2015

There are no references for this article.